TITLE

Short-Term Efficacy and Safety of Leflunomide in the Treatment of Active Rheumatoid Arthritis in Everyday Clinical Use

AUTHOR(S)
Minh Nguyen; Marmar Kabir, D.; Ravaud, Philippe
PUB. DATE
February 2004
SOURCE
Clinical Drug Investigation;2004, Vol. 24 Issue 2, p103
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To determine the efficacy and safety profile of 6-month treatment with leflunomide 20mg daily in patients with acute rheumatoid arthritis (RA) receiving treatment from 197 office-based rheumatologists in France. Methods: This open-label, prospective, multicentre study included 378 ambulatory RA patients who received leflunomide at a loading dose of 100mg daily on days 1-3, followed by 20mg daily for 6 months. The primary efficacy endpoint was a ≥20% response according to the American College of Rheumatology criteria (ACR 20) after 6 months. Secondary efficacy criteria were a ≥50% response (ACR 50) and a ≥70% response (ACR 70), as well as disease activity score (DAS28) responses. Results: Among the 407 selected patients, 378 patients were included in the study, all of whom were treated with leflunomide. Female patients made up 78.6% of the study population; the mean age was 57.7 ± 12.0 years, and the mean disease duration was 9.7 ± 8.5 years. At 6 months, the ACR 20 response rate was 48.2% (95% confidence interval [CI] 43-53%). ACR 50 and 70 response rates were 25.3% (95% CI 21.0-30.1) and 11.7% (95% CI 8.6-15.4%), respectively. According to the DAS28, 21.8% of patients had a good response, 39.9% a moderate response, and 38.2% were non-responders. The DAS28 response rate was thus 61.8% (95% CI 56.5-66.9%). Mean improvements in tender joint count were -5.6 ± 7.4 (from baseline of 12.2± 6.7), in swollen joint count were -4.2 ±5.7 (from baseline of 9.8 ± 5.8), and in investigator's global assessment of RA disease activity were -20.2± 25.1 (from baseline of 51.6 ± 17.1). Treatment-related adverse events caused 15.9% of patients to discontinue the study prematurely. Serious adverse events possibly related to therapy were reported in 2.4% of patients. Conclusions: This 6-month study carried out under daily routine practice conditions in a typical sample of RA patients showed a favourable efficacy and safety profile for leflunomide 20mg daily. The study confirms the findings of the earlier phase II and III study programme in more selected patient samples.
ACCESSION #
12753463

 

Related Articles

  • Leflunomide: An immunomodulatory agent for the treatment of rheumatoid arthritis. Dunn, Erin C.; Small, Ralph E. // Formulary;Jan1999, Vol. 34 Issue 1, p21 

    Presents information about leflunomide, an immunomodulatory agent for the treatment of rheumatoid arthritis. Chemistry and pharmacology; Pharmacokinetics; Clinical trials; Adverse effects; Drug interactions; Dosing and administration. INSET: Formulary Considerations.

  • Droitwich lecture. McInnes, Iain // Rheumatology;Apr2011 Supplement 3, Vol. 50 Issue suppl_3, piii15 

    The immune system has evolved over millennia to protect the host from overwhelming infectious disease. The mechanisms that allow effective defence have also evolved local regulatory pathways that prevent undue damage to the host tissues in the course of such defence, so called collateral damage....

  • Newer Immunosuppressive Drugs: Their Potential Role in Rheumatoid Arthritis Therapy. Drosos, A.A. // Drugs;2002, Vol. 62 Issue 6, p891 

    Rheumatoid arthritis (RA) is a chronic immune-mediated disease characterised by chronic synovitis, which leads to cartilage damage and joint destruction. It is generally a progressive disease with radiographic evidence of joint damage, functional status decline and premature mortality....

  • Immunosuppressive drugs in rheumatoid arthritis. Baum, John; Vaughan, John; Baum, J; Vaughan, J // Annals of Internal Medicine;Jul69, Vol. 71 Issue 1, p202 

    Editorial. Focuses on immunosuppressive therapy for the treatment of rheumatoid arthritis. Information on immunosuppressive agents; Efficacy of the agent; Mechanism of action and dosage; Side effects and contraindications.

  • Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Miyagawa, Ippei; Nakayamada, Shingo; Saito, Kazuyoshi; Hanami, Kentaro; Nawata, Masao; Sawamukai, Norifumi; Nakano, Kazuhisa; Yamaoka, Kunihiro; Tanaka, Yoshiya // Modern Rheumatology (Springer Science & Business Media B.V.);May2014, Vol. 24 Issue 3, p405 

    Objectives: Although treatment of rheumatoid arthritis (RA) has progressed by the use of biologics, amyloid A (AA) amyloidosis is still an intractable complication in patients with RA. In the present study, safety and efficacy of 1-year treatment with an anti-IL-6 receptor antibody tocilizumab...

  • The Trends of DMARDS prescribed in Rheumatoid Arthritis Patients in Malaysia. Sulaiman, Wahinuddin; Toib, Ashraful; Chandrashehar, Giriyappanavar; Arshad, Anwar // Oman Medical Journal;Oct2009, Vol. 24 Issue 4, p260 

    Objectives: : To evaluate the trends of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of rheumatoid arthritis (RA). Methods: Patients who fulfilled the ACR criteria for RA from 1995 to 2006 and who attended the Rheumatology clinic at Ipoh Hospital were selected and their...

  • Intermittent cyclophosphamide in refractory rheumatoid arthritis. Horslev-Petersen, Kim; Beyer, Jannie M.; Helin, Pekka // British Medical Journal (Clinical Research Edition);9/10/1983, Vol. 287 Issue 6394, p711 

    Examines the effectiveness of cyclophosphamide and methylprednisolone in treating patients with refractory rheumatoid arthritis. Importance of cyclophosphamide reduction on leucopenia development; Use of immunosuppressive agents in rheumatoid arthritis management; Relationship between bladder...

  • Risk for Zoster from the Vaccine in Immunosuppressed Persons.  // OB/GYN Clinical Alert;Sep2012 Clinical Briefs in Primary Care, p17 

    The article focuses on the restricted use of herpes zoster vaccine (ZOS) for the person who receives immunosuppressive treatments such as methotrexate for rheumatoid arthritis as ZOS is a live virus.

  • Tocilizumab cost effective in MTX-intolerant RA.  // PharmacoEconomics & Outcomes News;7/21/2012, Issue 658, p3 

    The article discusses research on the cost effectiveness of tocilizumab in patients with rheumatoid arthritis who are intolerant or have contraindications to methotrexate, referencing a study by C. Gibbons et al presented at the 13th Annual Congress of the European League Against Rheumatism.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics